Coriolan Lebreton, Stanislas Quesada, Marta Bini, Guillaume Babin, Léa Rossi, Nicolas Chopin, Sabrina Croce, Cécile Hartog, Tiphaine Renaud, Anne-Lise Gaillard, Adeline Petit, Anne-Agathe Serre, Olivier Trédan, Elise Rowinski, Vincent Cockenpot, Isabelle Treilleux, Christine Rousset-Jablonski, Pierre Méeus, Frédéric Guyon, Isabelle Ray-Coquard
Bull Cancer. 2023 Jul-Aug;110(7-8):818-824. Epub 2023 Apr 10.
Abstract
Even if each rare ovarian tumor (ROT) has a low incidence, the sum of all these entities represents almost the half of all ovarian neoplasms. Thus, development of dedicated clinical trial emerged as a prerequisite to improve their managements. Owing to the spreading of dedicated institutional networks and (supra)national collaborations, the number of clinical trials has increased the past few years, with different types of trials; while some focused on specific molecular features, others assessed innovative molecules. Furthermore, relevant randomized clinical trials were designed as a mean to position new treatment options. Currently, innovative molecular-driven trials, based on master protocol trials are emerging and may shed light towards the improvement of personalized medicine regarding ROT.
PMID: 37045734 DOI: 10.1016/j.bulcan.2023.03.007
